Nationwide Children's Hospital

The University of Western Australia

Nicolas Wein

Scott Quenton Harper

Kevin Flanigan

Adeline Vulin-Chaffiol

Stephen Donald Wilton

Kelly Reed Clark

RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DYSTROPHIA MYOTONICA PROTEIN KINASE AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3' UNTRANSLATED REGION OF THE DMPK GENE

The present invention relates to methods for shifting the splicing profile of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding U7-based small nuclear RNAs to induce DUX4 exon-skipping and the expression of shortened forms of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.

Recombinant virus products and methods for inducing DUX4 exon skipping

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs

The present invention relates to the delivery of oligomers for treating patients with a 5' mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5&#x2032; mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.

Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene

Growing community of inventors

Columbus, OH, United States of America

Nicolas Wein